Analysis of SGLT2 inhibitor RCTs showed consistent reductions in MACE, HF hospitalization, and CKD progression regardless of baseline GLP-1RA use, as demonstrated by a recent SMART-C consortium analysis of over 73,000 individuals with T2D [13]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.